Literature DB >> 29140606

MR textural analysis on T2 FLAIR images for the prediction of true oligodendroglioma by the 2016 WHO genetic classification.

Wenting Rui1, Yan Ren1, Yin Wang2, Xinyi Gao1, Xiao Xu3, Zhenwei Yao1.   

Abstract

BACKGROUND: The genetic status of 1p/19q is important for differentiating oligodendroglioma, isocitrate-dehydrogenase (IDH)-mutant, and 1p/19q-codeleted from diffuse astrocytoma, IDH-mutant according to the 2016 World Health Organization (WHO) criteria.
PURPOSE: To assess the value of magnetic resonance textural analysis (MRTA) on T2 fluid-attenuated inversion recovery (FLAIR) images for making a genetically integrated diagnosis of true oligodendroglioma by WHO guidelines. STUDY TYPE: Retrospective case control.
SUBJECTS: In all, there were 54 patients with a histopathological diagnosis of diffuse glioma (grade II). All were tested for IDH and 1p/19q. FIELD STRENGTH/SEQUENCE: 3.0T, including T2 FLAIR sequence, axial T1 -weighted, and T2 -weighted sequence. ASSESSMENT: MRTA on a representative tumor region of interest (ROI) was made on preoperative T2 FLAIR images around the area that had the largest diameter of solid tumor using Omni Kinetics software. STATISTICAL TESTS: Differences between IDH-mutant and 1p/19q-codeleted and IDH-mutant and 1p/19q-intact gliomas were analyzed by the Mann-Whitney rank sum test. Receiver operating characteristic curves (ROC) were created to assess MRTA diagnostic performance. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated with a cutoff value according to the Youden Index.
RESULTS: Comparisons demonstrated significant differences in kurtosis (P = 0.007), energy (0.008), entropy (0.008), mean deviation (MD) (<0.001), and high gray-level run emphasis (HGLRE) (0.002), cluster shade (0.025), and sum average (0.002). First-order features comprising entropy (area under the curve [AUC] = 0.718, sensitivity = 97.1%) and energy (0.719, 94.1%) had the highest sensitivity but lower specificity (both 45%). Second-order features such as HGLRE (AUC = 0.750, sensitivity = 73.5%, specificity = 80.0%) and sum average (0.751, 70.6%, 80.0%) had relatively higher specificity, and all had AUC >0.7. MD had the highest diagnostic performance, with AUC = 0.878, sensitivity = 94.1%, specificity = 75.0%, PPV = 86.5%, and NPV = 88.2%. DATA
CONCLUSION: MRTA on T2 FLAIR images may be helpful in identifying oligodendroglioma, IDH-mutant, and 1p/19q-codeleted. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2017.
© 2017 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  1p/19q; IDH-mutant; T2 FLAIR; magnetic resonance textural analysis; oligodendroglioma

Mesh:

Substances:

Year:  2017        PMID: 29140606     DOI: 10.1002/jmri.25896

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

1.  Radiomics for intracerebral hemorrhage: are all small hematomas benign?

Authors:  Chenyi Zhan; Qian Chen; Mingyue Zhang; Yilan Xiang; Jie Chen; Dongqin Zhu; Chao Chen; Tianyi Xia; Yunjun Yang
Journal:  Br J Radiol       Date:  2020-12-17       Impact factor: 3.039

2.  Predictive value of pretreatment MRI texture analysis in patients with primary nasopharyngeal carcinoma.

Authors:  Jiaji Mao; Jin Fang; Xiaohui Duan; Zehong Yang; Minghui Cao; Fang Zhang; Liejing Lu; Xiang Zhang; Xiaoyan Wu; Yue Ding; Jun Shen
Journal:  Eur Radiol       Date:  2019-01-07       Impact factor: 5.315

3.  A Nomogram Model of Radiomics and Satellite Sign Number as Imaging Predictor for Intracranial Hematoma Expansion.

Authors:  Wen Xu; Zhongxiang Ding; Yanna Shan; Wenhui Chen; Zhan Feng; Peipei Pang; Qijun Shen
Journal:  Front Neurosci       Date:  2020-06-04       Impact factor: 4.677

4.  High-order radiomics features based on T2 FLAIR MRI predict multiple glioma immunohistochemical features: A more precise and personalized gliomas management.

Authors:  Jing Li; Siyun Liu; Ying Qin; Yan Zhang; Ning Wang; Huaijun Liu
Journal:  PLoS One       Date:  2020-01-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.